NASDAQ: IVA - Inventiva S.A.

Yield per half year: +34.84%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Inventiva S.A.

Extended chart Simple chart
Financial Markets by TradingView

About Inventiva S.A.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-07-10
ISIN US46124U1079
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.inventivapharma.com
Цена ао 3
Change price per day: -0.6667% (3)
Change price per week: -4.18% (3.11)
Change price per month: +24.17% (2.4)
Change price per 3 month: +21.63% (2.45)
Change price per half year: +34.84% (2.21)
Change price per year: -25.69% (4.01)
Change price per 3 year: -73.46% (11.23)
Change price per 5 year: 0% (2.98)
Change price per 10 year: 0% (2.98)
Change price per year to date: +34.95% (2.2082)
All parameters

Underestimation

Title Value Grade
P/S 10.36 1
P/BV -6.17 0
P/E 0 0
EV/EBITDA -1.81 0
Total: 3.75

Efficiency

Title Value Grade
ROA, % -176.54 0
ROE, % 376.22 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2841 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 150 10
Yield Ebitda, % 272.73 10
Yield EPS, % 83.33 9
Total: 9.8
More

Institutions Volume Share, %
Yiheng Capital Management, L.P. 2644926 5.08
NEA Management Company, LLC 1462586 2.81
BVF Inc. 686040 1.32
Commonwealth Equity Services, LLC 36265 0.07
TWO SIGMA SECURITIES, LLC 13005 0.02
Ewa, LLC 11898 0.02
Morgan Stanley 5900 0.01
UBS Group AG 254 0



Head Job title Payment Year of birth
Mr. Frederic Cren Co-Founder, CEO & Chairman 521.29k 1966 (59 years)
Dr. Pierre Broqua Ph.D. Co-Founder, Chief Scientific Officer, Deputy CEO & Director 450.22k 1962 (63 years)
Mr. Jean Volatier Deputy GM & CFO N/A 1964 (61 year)
Mr. Eric Duranson L.L.M. General Counsel N/A 1974 (51 year)
Ms. Nathalie Harroy Head of Human Resources N/A 1967 (58 years)
Dr. Michael Cooreman Chief Medical Officer N/A 1958 (67 years)
Ms. Alice Roudot-Ketelers Pharm.D. Chief Operating Officer N/A 1971 (54 years)
Ms. Pascaline Clerc Ph.D. Executive Vice President of Strategy & Corporate Affairs N/A 1980 (45 years)
Dr. Kristina Meyer Ph.D. Executive VP and Business Development & Alliance Management

Address: France, Daix, 50 rue de Dijon - open in Google maps, open in Yandex maps
Website: https://www.inventivapharma.com